 Samuel Gubbels
Concepts (348)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cochlear Implants | 6 | 2021 | 76 | 2.970 |
Why?
| | Neuroma, Acoustic | 6 | 2021 | 18 | 2.690 |
Why?
| | Hearing Loss | 6 | 2018 | 161 | 2.500 |
Why?
| | Cochlear Implantation | 6 | 2021 | 62 | 2.420 |
Why?
| | Cochlea | 8 | 2021 | 84 | 2.230 |
Why?
| | Hearing | 7 | 2021 | 113 | 1.810 |
Why?
| | Semicircular Canals | 4 | 2021 | 29 | 1.730 |
Why?
| | Speech Perception | 4 | 2021 | 82 | 1.440 |
Why?
| | Otitis Media | 7 | 2022 | 127 | 1.350 |
Why?
| | Radiosurgery | 3 | 2019 | 299 | 1.260 |
Why?
| | Ear, Inner | 5 | 2020 | 34 | 1.240 |
Why?
| | Nestin | 2 | 2016 | 17 | 1.220 |
Why?
| | Otitis Media with Effusion | 3 | 2014 | 20 | 1.110 |
Why?
| | Nasopharyngeal Diseases | 2 | 2014 | 5 | 1.040 |
Why?
| | Unnecessary Procedures | 2 | 2014 | 47 | 0.990 |
Why?
| | Labyrinth Diseases | 3 | 2020 | 10 | 0.910 |
Why?
| | Endoscopy | 3 | 2020 | 239 | 0.900 |
Why?
| | Human Embryonic Stem Cells | 1 | 2021 | 20 | 0.890 |
Why?
| | Hair Cells, Auditory, Inner | 1 | 2021 | 15 | 0.870 |
Why?
| | Deafness | 3 | 2018 | 78 | 0.840 |
Why?
| | Pluripotent Stem Cells | 1 | 2021 | 66 | 0.840 |
Why?
| | Otolaryngologists | 1 | 2020 | 9 | 0.830 |
Why?
| | Hair Cells, Auditory | 4 | 2021 | 35 | 0.800 |
Why?
| | Paraganglioma | 1 | 2020 | 36 | 0.780 |
Why?
| | Tinnitus | 3 | 2018 | 47 | 0.770 |
Why?
| | Skull Base Neoplasms | 1 | 2019 | 22 | 0.770 |
Why?
| | Audiometry, Pure-Tone | 4 | 2018 | 23 | 0.750 |
Why?
| | Eustachian Tube | 1 | 2018 | 3 | 0.740 |
Why?
| | Ear Neoplasms | 1 | 2018 | 4 | 0.740 |
Why?
| | Meningioma | 1 | 2019 | 69 | 0.730 |
Why?
| | Meningeal Neoplasms | 1 | 2019 | 79 | 0.720 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2018 | 53 | 0.700 |
Why?
| | Hearing Aids | 2 | 2016 | 57 | 0.690 |
Why?
| | Vertigo | 2 | 2018 | 30 | 0.680 |
Why?
| | Radiation Injuries | 1 | 2018 | 136 | 0.660 |
Why?
| | Physicians' Offices | 1 | 2016 | 19 | 0.640 |
Why?
| | Surgical Flaps | 2 | 2016 | 125 | 0.620 |
Why?
| | Suture Anchors | 1 | 2016 | 32 | 0.600 |
Why?
| | Skin Transplantation | 1 | 2016 | 57 | 0.600 |
Why?
| | Membrane Proteins | 2 | 2020 | 1083 | 0.590 |
Why?
| | Magnetic Resonance Imaging | 5 | 2019 | 3145 | 0.590 |
Why?
| | Sex Characteristics | 1 | 2021 | 686 | 0.590 |
Why?
| | Head and Neck Neoplasms | 1 | 2020 | 420 | 0.580 |
Why?
| | Device Removal | 1 | 2016 | 116 | 0.560 |
Why?
| | Cranial Fossa, Middle | 2 | 2020 | 7 | 0.560 |
Why?
| | Benign Paroxysmal Positional Vertigo | 3 | 2021 | 5 | 0.560 |
Why?
| | Bacteriological Techniques | 1 | 2014 | 62 | 0.550 |
Why?
| | Blood | 1 | 2014 | 104 | 0.540 |
Why?
| | Hyperacusis | 1 | 2014 | 10 | 0.540 |
Why?
| | Cell Differentiation | 2 | 2021 | 1807 | 0.530 |
Why?
| | Humans | 54 | 2022 | 114571 | 0.530 |
Why?
| | Cholesteatoma | 1 | 2014 | 9 | 0.530 |
Why?
| | Tomography, X-Ray Computed | 7 | 2016 | 2379 | 0.530 |
Why?
| | Hearing Loss, Sensorineural | 5 | 2018 | 54 | 0.500 |
Why?
| | Temporal Bone | 5 | 2017 | 39 | 0.500 |
Why?
| | Jugular Veins | 1 | 2013 | 40 | 0.490 |
Why?
| | Bacteremia | 1 | 2014 | 159 | 0.490 |
Why?
| | Carotid Body Tumor | 1 | 2012 | 1 | 0.490 |
Why?
| | Glomus Jugulare Tumor | 1 | 2012 | 5 | 0.490 |
Why?
| | Polyvinyls | 1 | 2012 | 15 | 0.490 |
Why?
| | Reconstructive Surgical Procedures | 3 | 2021 | 253 | 0.490 |
Why?
| | Carotid Artery, Internal | 1 | 2012 | 25 | 0.480 |
Why?
| | Influenza B virus | 1 | 2012 | 35 | 0.480 |
Why?
| | Creutzfeldt-Jakob Syndrome | 1 | 2012 | 18 | 0.470 |
Why?
| | Cranial Nerve Diseases | 1 | 2012 | 45 | 0.470 |
Why?
| | Patient Selection | 1 | 2016 | 707 | 0.470 |
Why?
| | Mutation | 2 | 2020 | 3378 | 0.460 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2016 | 743 | 0.460 |
Why?
| | Denmark | 5 | 2016 | 31 | 0.450 |
Why?
| | Embolization, Therapeutic | 1 | 2012 | 101 | 0.440 |
Why?
| | Influenza A virus | 1 | 2012 | 109 | 0.440 |
Why?
| | Melanoma | 1 | 2018 | 718 | 0.440 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2012 | 144 | 0.420 |
Why?
| | Nerve Tissue Proteins | 1 | 2015 | 613 | 0.410 |
Why?
| | Otologic Surgical Procedures | 4 | 2021 | 15 | 0.410 |
Why?
| | Fucosyltransferases | 2 | 2022 | 27 | 0.410 |
Why?
| | Aging | 2 | 2021 | 1708 | 0.400 |
Why?
| | Genetic Therapy | 5 | 2020 | 268 | 0.390 |
Why?
| | Middle Aged | 18 | 2019 | 28854 | 0.390 |
Why?
| | Retrospective Studies | 13 | 2021 | 11642 | 0.380 |
Why?
| | Transfection | 2 | 2009 | 965 | 0.380 |
Why?
| | Bacteria | 1 | 2014 | 655 | 0.360 |
Why?
| | Male | 27 | 2021 | 60817 | 0.360 |
Why?
| | Cerebrospinal Fluid Otorrhea | 1 | 2007 | 6 | 0.350 |
Why?
| | Encephalocele | 1 | 2007 | 6 | 0.350 |
Why?
| | Intensive Care Units | 1 | 2012 | 592 | 0.350 |
Why?
| | Nasopharynx | 2 | 2022 | 60 | 0.350 |
Why?
| | Urinary Tract Infections | 2 | 2022 | 126 | 0.350 |
Why?
| | Female | 23 | 2021 | 63070 | 0.340 |
Why?
| | Uterus | 1 | 2008 | 192 | 0.330 |
Why?
| | Hearing Tests | 2 | 2020 | 53 | 0.330 |
Why?
| | Cross Infection | 2 | 2022 | 203 | 0.320 |
Why?
| | Adult | 18 | 2021 | 32077 | 0.320 |
Why?
| | Influenza, Human | 1 | 2012 | 516 | 0.310 |
Why?
| | Tracheal Diseases | 1 | 2006 | 16 | 0.310 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2008 | 242 | 0.310 |
Why?
| | Neurons | 1 | 2015 | 1407 | 0.310 |
Why?
| | Bioprosthesis | 1 | 2006 | 43 | 0.310 |
Why?
| | Animals | 15 | 2022 | 34687 | 0.290 |
Why?
| | Airway Obstruction | 1 | 2006 | 155 | 0.270 |
Why?
| | Mice | 9 | 2022 | 15429 | 0.270 |
Why?
| | Trachea | 1 | 2006 | 222 | 0.270 |
Why?
| | Incidence | 5 | 2016 | 2454 | 0.260 |
Why?
| | Audiometry | 2 | 2014 | 33 | 0.260 |
Why?
| | Otorhinolaryngologic Diseases | 1 | 2003 | 16 | 0.260 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2003 | 38 | 0.250 |
Why?
| | Aged | 12 | 2021 | 20218 | 0.250 |
Why?
| | Synapses | 2 | 2021 | 314 | 0.240 |
Why?
| | Treatment Outcome | 8 | 2021 | 9190 | 0.240 |
Why?
| | Haemophilus Infections | 1 | 2022 | 34 | 0.230 |
Why?
| | Microsurgery | 2 | 2020 | 51 | 0.220 |
Why?
| | Labyrinthitis | 1 | 2021 | 1 | 0.220 |
Why?
| | Otolithic Membrane | 1 | 2021 | 4 | 0.220 |
Why?
| | Stem Cell Transplantation | 2 | 2021 | 151 | 0.220 |
Why?
| | Neurons, Efferent | 1 | 2021 | 10 | 0.220 |
Why?
| | Aged, 80 and over | 6 | 2016 | 6818 | 0.220 |
Why?
| | Intestinal Mucosa | 1 | 2006 | 517 | 0.220 |
Why?
| | Vestibular Diseases | 1 | 2021 | 22 | 0.220 |
Why?
| | Microbiota | 3 | 2022 | 498 | 0.220 |
Why?
| | Vestibular Nerve | 1 | 2021 | 18 | 0.220 |
Why?
| | Plasminogen | 1 | 2020 | 38 | 0.210 |
Why?
| | Noise | 1 | 2021 | 57 | 0.210 |
Why?
| | Stapes Surgery | 1 | 2020 | 6 | 0.200 |
Why?
| | Mice, Transgenic | 2 | 2016 | 2101 | 0.200 |
Why?
| | Ear, Middle | 4 | 2022 | 80 | 0.200 |
Why?
| | Cadaver | 4 | 2020 | 303 | 0.200 |
Why?
| | Magnets | 1 | 2019 | 13 | 0.200 |
Why?
| | alpha-Macroglobulins | 1 | 2019 | 20 | 0.190 |
Why?
| | Laser Therapy | 1 | 2020 | 94 | 0.190 |
Why?
| | Artifacts | 1 | 2019 | 115 | 0.180 |
Why?
| | Hearing Loss, Sudden | 1 | 2018 | 8 | 0.180 |
Why?
| | Hearing Loss, Bilateral | 1 | 2018 | 17 | 0.180 |
Why?
| | Mutation, Missense | 1 | 2020 | 307 | 0.180 |
Why?
| | Mucous Membrane | 1 | 2018 | 116 | 0.170 |
Why?
| | Surgical Equipment | 1 | 2017 | 13 | 0.170 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2018 | 107 | 0.170 |
Why?
| | Hospitals | 3 | 2022 | 502 | 0.170 |
Why?
| | Neurotology | 1 | 2017 | 1 | 0.170 |
Why?
| | Mice, Inbred C57BL | 3 | 2018 | 5137 | 0.170 |
Why?
| | Genetic Testing | 1 | 2020 | 366 | 0.170 |
Why?
| | Hearing Loss, Noise-Induced | 1 | 2017 | 18 | 0.170 |
Why?
| | Infant | 7 | 2019 | 8096 | 0.160 |
Why?
| | Dissection | 1 | 2017 | 51 | 0.160 |
Why?
| | Green Fluorescent Proteins | 2 | 2016 | 417 | 0.160 |
Why?
| | Patient Positioning | 1 | 2017 | 51 | 0.160 |
Why?
| | Regeneration | 1 | 2018 | 175 | 0.160 |
Why?
| | Down-Regulation | 1 | 2019 | 663 | 0.150 |
Why?
| | Hearing Loss, Unilateral | 1 | 2016 | 8 | 0.150 |
Why?
| | Child, Preschool | 7 | 2019 | 9651 | 0.150 |
Why?
| | Automation | 1 | 2016 | 77 | 0.150 |
Why?
| | Scalp | 1 | 2016 | 25 | 0.150 |
Why?
| | Sequence Analysis, DNA | 1 | 2019 | 734 | 0.150 |
Why?
| | Epidemiological Monitoring | 1 | 2016 | 48 | 0.150 |
Why?
| | Electrodes, Implanted | 1 | 2016 | 109 | 0.150 |
Why?
| | Organogenesis | 1 | 2016 | 56 | 0.150 |
Why?
| | Diagnosis, Differential | 5 | 2021 | 1419 | 0.150 |
Why?
| | Pharmaceutical Preparations | 1 | 2018 | 172 | 0.150 |
Why?
| | Plant Lectins | 1 | 2015 | 10 | 0.150 |
Why?
| | Ifosfamide | 1 | 2015 | 32 | 0.150 |
Why?
| | Age Factors | 3 | 2012 | 3280 | 0.150 |
Why?
| | Estrogen Antagonists | 1 | 2015 | 45 | 0.140 |
Why?
| | Durapatite | 2 | 2021 | 48 | 0.140 |
Why?
| | Ki-67 Antigen | 1 | 2015 | 108 | 0.140 |
Why?
| | Etoposide | 1 | 2015 | 157 | 0.140 |
Why?
| | Audiology | 1 | 2014 | 12 | 0.140 |
Why?
| | Adolescent | 7 | 2019 | 18658 | 0.140 |
Why?
| | Educational Measurement | 1 | 2017 | 298 | 0.140 |
Why?
| | Child | 8 | 2019 | 17859 | 0.130 |
Why?
| | Pedigree | 3 | 2020 | 477 | 0.130 |
Why?
| | Tamoxifen | 1 | 2015 | 203 | 0.130 |
Why?
| | Methotrexate | 1 | 2015 | 240 | 0.130 |
Why?
| | Animals, Newborn | 1 | 2016 | 843 | 0.130 |
Why?
| | Luminescent Proteins | 1 | 2015 | 182 | 0.130 |
Why?
| | Young Adult | 6 | 2019 | 10987 | 0.130 |
Why?
| | Head Injuries, Closed | 2 | 2014 | 48 | 0.130 |
Why?
| | Eye Movement Measurements | 1 | 2013 | 12 | 0.130 |
Why?
| | Vestibular Evoked Myogenic Potentials | 1 | 2013 | 6 | 0.130 |
Why?
| | Reproducibility of Results | 3 | 2017 | 2926 | 0.130 |
Why?
| | Genetic Variation | 1 | 2018 | 824 | 0.130 |
Why?
| | Hearing Loss, Mixed Conductive-Sensorineural | 1 | 2012 | 4 | 0.120 |
Why?
| | Central Nervous System Cysts | 1 | 2012 | 12 | 0.120 |
Why?
| | Oral Surgical Procedures | 2 | 2011 | 8 | 0.120 |
Why?
| | Salmonella Food Poisoning | 1 | 2012 | 8 | 0.120 |
Why?
| | Quality of Life | 2 | 2021 | 2230 | 0.120 |
Why?
| | Meat Products | 1 | 2012 | 8 | 0.120 |
Why?
| | Food Contamination | 1 | 2012 | 24 | 0.120 |
Why?
| | Laryngoscopy | 1 | 2013 | 68 | 0.120 |
Why?
| | Disease Notification | 1 | 2012 | 17 | 0.120 |
Why?
| | Vestibule, Labyrinth | 1 | 2012 | 49 | 0.120 |
Why?
| | Seasons | 1 | 2014 | 438 | 0.120 |
Why?
| | Follow-Up Studies | 5 | 2010 | 4950 | 0.120 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1561 | 0.120 |
Why?
| | Phenotype | 1 | 2020 | 2842 | 0.120 |
Why?
| | Biomedical Research | 1 | 2018 | 585 | 0.110 |
Why?
| | Receptors, Estrogen | 1 | 2015 | 390 | 0.110 |
Why?
| | Foodborne Diseases | 1 | 2012 | 30 | 0.110 |
Why?
| | Disease Progression | 1 | 2019 | 2486 | 0.110 |
Why?
| | Labyrinth Supporting Cells | 1 | 2011 | 3 | 0.110 |
Why?
| | Organ of Corti | 1 | 2011 | 7 | 0.110 |
Why?
| | Temporomandibular Joint Disorders | 1 | 2011 | 8 | 0.110 |
Why?
| | Viral Tropism | 1 | 2011 | 27 | 0.110 |
Why?
| | Skull Base | 2 | 2021 | 36 | 0.110 |
Why?
| | Ear Canal | 1 | 2011 | 13 | 0.110 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 1994 | 0.110 |
Why?
| | Ganglion Cysts | 1 | 2011 | 9 | 0.110 |
Why?
| | Age Distribution | 1 | 2012 | 396 | 0.110 |
Why?
| | Neurosurgical Procedures | 1 | 2012 | 145 | 0.110 |
Why?
| | Dependovirus | 1 | 2011 | 54 | 0.110 |
Why?
| | Cranial Nerve Neoplasms | 1 | 2010 | 6 | 0.110 |
Why?
| | Sex Distribution | 1 | 2012 | 390 | 0.110 |
Why?
| | Ear Diseases | 1 | 2011 | 15 | 0.110 |
Why?
| | Radiography | 1 | 2014 | 850 | 0.110 |
Why?
| | Zygoma | 1 | 2010 | 7 | 0.110 |
Why?
| | Sex Factors | 2 | 2014 | 1971 | 0.100 |
Why?
| | Adenoviridae | 1 | 2011 | 184 | 0.100 |
Why?
| | Salmonella typhimurium | 1 | 2012 | 183 | 0.100 |
Why?
| | Sensitivity and Specificity | 2 | 2013 | 1920 | 0.100 |
Why?
| | Magnetic Resonance Angiography | 1 | 2012 | 235 | 0.100 |
Why?
| | Gene Transfer Techniques | 1 | 2011 | 149 | 0.100 |
Why?
| | Cost of Illness | 1 | 2012 | 296 | 0.100 |
Why?
| | Genetic Vectors | 1 | 2011 | 322 | 0.100 |
Why?
| | Clinical Competence | 1 | 2017 | 935 | 0.100 |
Why?
| | Abscess | 1 | 2010 | 80 | 0.100 |
Why?
| | Electroencephalography | 1 | 2012 | 501 | 0.100 |
Why?
| | Prospective Studies | 3 | 2012 | 6288 | 0.100 |
Why?
| | Disease Outbreaks | 1 | 2012 | 291 | 0.100 |
Why?
| | Maxilla | 1 | 2009 | 33 | 0.100 |
Why?
| | Skull Fractures | 1 | 2009 | 22 | 0.100 |
Why?
| | Gene Expression Regulation | 2 | 2019 | 2555 | 0.090 |
Why?
| | Electroporation | 1 | 2009 | 29 | 0.090 |
Why?
| | Middle Ear Ventilation | 1 | 2008 | 15 | 0.090 |
Why?
| | Electric Conductivity | 1 | 2008 | 90 | 0.090 |
Why?
| | Dyneins | 1 | 2008 | 24 | 0.090 |
Why?
| | Cleft Lip | 1 | 2008 | 33 | 0.090 |
Why?
| | Population Surveillance | 1 | 2012 | 440 | 0.090 |
Why?
| | Comorbidity | 1 | 2014 | 1645 | 0.090 |
Why?
| | Cell Proliferation | 1 | 2016 | 2368 | 0.090 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 661 | 0.090 |
Why?
| | Cleft Palate | 1 | 2008 | 43 | 0.090 |
Why?
| | Evidence-Based Medicine | 1 | 2013 | 728 | 0.090 |
Why?
| | Swine | 2 | 2012 | 725 | 0.090 |
Why?
| | Myosins | 1 | 2008 | 128 | 0.090 |
Why?
| | Imaging, Three-Dimensional | 1 | 2012 | 546 | 0.090 |
Why?
| | Disease Models, Animal | 2 | 2008 | 3828 | 0.090 |
Why?
| | Bone Cements | 1 | 2007 | 37 | 0.080 |
Why?
| | Craniotomy | 1 | 2007 | 65 | 0.080 |
Why?
| | Chronic Disease | 1 | 2014 | 1648 | 0.080 |
Why?
| | Mechanotransduction, Cellular | 1 | 2008 | 97 | 0.080 |
Why?
| | Internship and Residency | 1 | 2017 | 987 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 1390 | 0.080 |
Why?
| | Neck Dissection | 1 | 2005 | 9 | 0.080 |
Why?
| | Tonsillar Neoplasms | 1 | 2005 | 9 | 0.080 |
Why?
| | Postoperative Care | 1 | 2007 | 237 | 0.080 |
Why?
| | Biomarkers | 1 | 2016 | 3485 | 0.070 |
Why?
| | Prevalence | 1 | 2012 | 2393 | 0.070 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2005 | 86 | 0.070 |
Why?
| | Neck | 1 | 2005 | 87 | 0.070 |
Why?
| | Random Allocation | 1 | 2006 | 395 | 0.070 |
Why?
| | Intestine, Small | 1 | 2006 | 145 | 0.070 |
Why?
| | Rabbits | 1 | 2006 | 794 | 0.070 |
Why?
| | Biopsy | 2 | 2011 | 1048 | 0.070 |
Why?
| | Safety | 1 | 2006 | 327 | 0.070 |
Why?
| | Models, Animal | 1 | 2006 | 389 | 0.070 |
Why?
| | Infant, Newborn | 1 | 2014 | 5045 | 0.070 |
Why?
| | Biocompatible Materials | 1 | 2007 | 368 | 0.060 |
Why?
| | Postoperative Complications | 2 | 2021 | 2181 | 0.060 |
Why?
| | Hearing Disorders | 1 | 2003 | 20 | 0.060 |
Why?
| | Antibodies, Antineutrophil Cytoplasmic | 1 | 2003 | 32 | 0.060 |
Why?
| | Hospitalization | 1 | 2012 | 1714 | 0.060 |
Why?
| | Algorithms | 3 | 2017 | 1502 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2012 | 3249 | 0.060 |
Why?
| | Eye Diseases | 1 | 2003 | 80 | 0.060 |
Why?
| | Haemophilus influenzae | 1 | 2022 | 49 | 0.060 |
Why?
| | Hydroxyapatites | 1 | 2021 | 23 | 0.060 |
Why?
| | Esthetics | 1 | 2021 | 34 | 0.060 |
Why?
| | Diagnostic Techniques, Otological | 1 | 2021 | 2 | 0.060 |
Why?
| | Lithiasis | 1 | 2021 | 3 | 0.060 |
Why?
| | Facial Nerve | 1 | 2021 | 30 | 0.050 |
Why?
| | Auditory Threshold | 2 | 2011 | 38 | 0.050 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2005 | 555 | 0.050 |
Why?
| | Infection Control | 1 | 2022 | 137 | 0.050 |
Why?
| | Nose | 1 | 2020 | 53 | 0.050 |
Why?
| | Scala Tympani | 1 | 2020 | 8 | 0.050 |
Why?
| | Pregnancy | 2 | 2009 | 5267 | 0.050 |
Why?
| | Surveys and Questionnaires | 1 | 2012 | 4741 | 0.050 |
Why?
| | Personal Satisfaction | 1 | 2021 | 179 | 0.050 |
Why?
| | Adrenal Cortex Hormones | 1 | 2003 | 510 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2022 | 473 | 0.050 |
Why?
| | Philippines | 1 | 2019 | 44 | 0.050 |
Why?
| | Finland | 1 | 2019 | 61 | 0.050 |
Why?
| | Lasers | 1 | 2020 | 115 | 0.050 |
Why?
| | Pakistan | 1 | 2019 | 72 | 0.050 |
Why?
| | Saliva | 1 | 2020 | 216 | 0.050 |
Why?
| | Pharmacokinetics | 1 | 2018 | 32 | 0.040 |
Why?
| | COS Cells | 1 | 2018 | 206 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2021 | 749 | 0.040 |
Why?
| | Incus | 1 | 2017 | 7 | 0.040 |
Why?
| | Exome | 1 | 2018 | 161 | 0.040 |
Why?
| | Ear Ossicles | 1 | 2017 | 15 | 0.040 |
Why?
| | Diffusion of Innovation | 1 | 2018 | 97 | 0.040 |
Why?
| | Stapes | 1 | 2017 | 31 | 0.040 |
Why?
| | Iatrogenic Disease | 1 | 2017 | 48 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 395 | 0.040 |
Why?
| | Pressure | 1 | 2017 | 275 | 0.040 |
Why?
| | Genomics | 1 | 2020 | 514 | 0.040 |
Why?
| | Statistics, Nonparametric | 1 | 2017 | 456 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2018 | 652 | 0.040 |
Why?
| | Forecasting | 1 | 2018 | 389 | 0.040 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2021 | 805 | 0.040 |
Why?
| | Speech Intelligibility | 1 | 2014 | 8 | 0.040 |
Why?
| | Drug Delivery Systems | 1 | 2018 | 336 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 734 | 0.030 |
Why?
| | Time | 1 | 2014 | 91 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2005 | 2035 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 1744 | 0.030 |
Why?
| | Abattoirs | 1 | 2012 | 2 | 0.030 |
Why?
| | Bacteriophage Typing | 1 | 2012 | 2 | 0.030 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2012 | 17 | 0.030 |
Why?
| | Minisatellite Repeats | 1 | 2012 | 50 | 0.030 |
Why?
| | Cues | 1 | 2014 | 302 | 0.030 |
Why?
| | Cell Line | 1 | 2018 | 2924 | 0.030 |
Why?
| | Microinjections | 1 | 2011 | 120 | 0.030 |
Why?
| | Transduction, Genetic | 1 | 2011 | 136 | 0.030 |
Why?
| | Evoked Potentials, Auditory, Brain Stem | 1 | 2011 | 52 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2019 | 2187 | 0.030 |
Why?
| | Acoustic Stimulation | 1 | 2011 | 374 | 0.020 |
Why?
| | Functional Laterality | 1 | 2010 | 251 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2011 | 435 | 0.020 |
Why?
| | Regression Analysis | 1 | 2012 | 1109 | 0.020 |
Why?
| | Trauma Severity Indices | 1 | 2009 | 141 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 2010 | 336 | 0.020 |
Why?
| | Gestational Age | 1 | 2011 | 762 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2011 | 1315 | 0.020 |
Why?
| | Probability | 1 | 2008 | 335 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2010 | 899 | 0.020 |
Why?
| | Stem Cells | 1 | 2011 | 549 | 0.020 |
Why?
| | RNA Interference | 1 | 2007 | 502 | 0.020 |
Why?
| | Fluorouracil | 1 | 2005 | 141 | 0.020 |
Why?
| | Signal Transduction | 1 | 2019 | 4890 | 0.020 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2005 | 327 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2005 | 313 | 0.020 |
Why?
| | Cisplatin | 1 | 2005 | 276 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2007 | 613 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2009 | 894 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2005 | 1004 | 0.010 |
Why?
| | United States | 1 | 2019 | 12551 | 0.010 |
Why?
| | Risk Assessment | 1 | 2008 | 3208 | 0.010 |
Why?
| | Time Factors | 1 | 2005 | 7029 | 0.010 |
Why?
|
|
Gubbels's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|